LYNCH Rosemary,ЛИНЧ Роузмэри,CANSFIELD Andrew David,КЭНСФИЛД Эндрю Дэвид,HARDY Daniel Paul,ХАРДИ Дэниел Пол,SUNOSE Mihiro,САНОСЕ Михиро,MOREL Adeline,МОРЕЛЬ Аделин,CONVERY Laura,КОНВЕРИ Лаура,ADREGO R
申请号：
RU2014109747
公开号：
RU0002616619C2
申请日:
2012.09.21
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) , where m equals 1 or 2 n equals 0, 1 or 2 each of R1 is independenly selected from the group consisting of C1-6alkyl, where C1-6alkyl is probably substitued with one R3 probably, two R1 are joint with a ring to which they are attached to form 8-membered heterobicycle R3 is OR4 R4 is H T0 is phenyl where T0 is substituted with the group N (R5a) C(O) N (R5bR5) R5a, R5b are independently selected from the group consisting of H R5 is T2 or C1-6alkyl, where C1-6alkyl is probably substituted with 1-4 R8, which are the same or different R8 is halogen OR9 N (R9R9a) R9, R9a are independently selected from the group consisting of H T2 is C3-7cycloalkyl 4-6-membered heterocyclyl, wherein 1 circular atom is substituted with oxygen heteroatom 6-membered aromatic heterocyclyl, wherein 1 circular atom is substituted with nitrogen heteroatom and phenyl, wherein T2 is probably substituted with one or two R10, which are the same or different R10 is halogen OR11 or C1-6alkyl, where C1-6alkyl is probably substituted with one R12 R11 is H R12 is OR13 R13 is H T1 is phenyl or 6-membered aromatic heterocycle, wherein 1 carbon atom is substituted with nitrogen heteroatom, wherein T1 is substituted with a group S(O)2R14 and is probably additionally substituted with one R15 R15 is halogen R14 is C1-6alkyl or unsubstituted 5-membered heterocyclyl ring, wherein 1 circular atom is substituted with nitrogen heteroatom. Compounds of formula (I) possess mTOR inhibitory activity. The invention also relates to a pharmaceutical composition, to compound application for drug manufacture and to a treatment method.EFFECT: new compounds of formula are obtained, which are useful for treatment or prevention of mTOR-related diseases and disorders.21 cl, 6 tbl, 44 exИзобретение относится к соединениям формулы (I)где m равно 1 или 2 n равно 0, 1 или 2 каждый R1 независимо выбран из группы, состоящей из С1-6алкила, где C1-6алкил возмо
